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ABSTRACT: Metabolic proﬁling studies aim to achieve broad metabolome coverage in speciﬁc biological samples. However,
wide metabolome coverage has proven diﬃcult to achieve, mostly because of the diverse physicochemical properties of small
molecules, obligating analysts to seek multiplatform and multimethod approaches. Challenges are even greater when it comes to
applications to tissue samples, where tissue lysis and metabolite extraction can induce signiﬁcant systematic variation in
composition. We have developed a pipeline for obtaining the aqueous and organic compounds from diseased arterial tissue using
two consecutive extractions, followed by a diﬀerent untargeted UPLC-MS analysis method for each extract. Methods were
rationally chosen and optimized to address the diﬀerent physicochemical properties of each extract: hydrophilic interaction liquid
chromatography (HILIC) for the aqueous extract and reversed-phase chromatography for the organic. This pipeline can be
generic for tissue analysis as demonstrated by applications to diﬀerent tissue types. The experimental setup and fast turnaround
time of the two methods contributed toward obtaining highly reproducible features with exceptional chromatographic
performance (CV % < 0.5%), making this pipeline suitable for metabolic proﬁling applications. We structurally assigned 226
metabolites from a range of chemical classes (e.g., carnitines, α-amino acids, purines, pyrimidines, phospholipids, sphingolipids,
free fatty acids, and glycerolipids) which were mapped to their corresponding pathways, biological functions and known disease
mechanisms. The combination of the two untargeted UPLC-MS methods showed high metabolite complementarity. We
demonstrate the application of this pipeline to cardiovascular disease, where we show that the analyzed diseased groups (n = 120)
of arterial tissue could be distinguished based on their metabolic proﬁles.
Metabolic proﬁling relies on the application of a range ofanalytical technologies to measure simultaneously diﬀer-
ential levels of multiple metabolites in biological matrices.1 It is
important to ensure wide metabolome coverage and con-
sequently enhance biomarker detection probability. For this an
untargeted format is the approach of choice warranting the
ability to detect unmapped metabolites and pathways, as well as
compounds originating from environmental interactions
unrelated to the biology of the system studied.2,3 To
compensate for the diﬀerent capabilities of each technique/
method, their bias toward speciﬁc classes of metabolites,4 and
the wide physicochemical diversity of the metabolome in a
biological matrix, multiple platforms5−8 and methods4 are
required to expand metabolite coverage.
Hydrophilic interaction liquid chromatography coupled to
mass spectrometry (HILIC-MS) is a relatively new chromato-
graphic tool applied in the eﬀort to expand metabolome
coverage. The importance of HILIC is attributed to its ability to
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generate proﬁles of mainly polar metabolites and is therefore
highly complementary to the traditionally used reversed-phase
(RP) chromatography.4 Several studies have demonstrated
superior partitioning abilities of HILIC columns for polar
compounds in biological matrices,4,9−11 predominantly urine
samples.9,10,12,13 However, the application of HILIC in
metabolic proﬁling studies continues to present unresolved
analytical challenges particularly with respect to chromato-
graphic performance.4,11,14,15
A previously described study aiming to expand metabolome
coverage combining RP-LC-MS and HILIC-MS was applied
using an HPLC system. This was translated into an extended 60
min run-time, and did not address tissue analysis.4 Moreover,
although a combination of RP-, HILIC-, and CE-MS has been
described by Saric et al.,5 it focused on evaluating the abilities of
single-extraction methodologies for Fasciola hepatica worms
rather than assessing biological pathway coverage of metabo-
lites detected.
Herein, we describe a combination of RP- and HILIC-
UPLC-MS methodologies functioning in an untargeted mode
with the aim of expanding metabolome coverage. We focused
on applying a UPLC-MS-based setup to tissue samples. Tissue
samples can provide unique information on physiological or
pathological mechanisms elucidation and biomarker discov-
ery.16,17 However, tissue lysis and metabolite extraction, as well
as establishing the appropriate analysis combination can be
challenging. We utilized a simple extraction format, based on
consecutive extraction steps,18 followed by a rational choice of
UPLC-MS analysis, according to the lipophilicity of the
extracts, wherein the aqueous extracts were analyzed using a
HILIC and organic extracts by a RP method. We applied the
method to proﬁle tissue from patients with cardiovascular
disease. The types of tissue used, such as atherosclerotic plaque,
have complex structure, intense presence of lipid molecules and
are biologically active. We evaluated the feasibility of analyzing
these complex tissue extracts, with emphasis on robust column
performance, stability, and longevity. The generic nature of the
presented pipeline was demonstrated with applications in
additional tissue types. A comprehensive structural assignment
of detected ions was performed, resulting in the generation of a
database of 226 unique structurally assigned metabolites. We
further demonstrated the complementarity of the two
chromatographic methods applied, and employed pathway
mapping tools to display their contribution to expanding the
coverage of metabolic pathways, biological functions, and
known disease mechanisms.
■ EXPERIMENTAL SECTION
A schematic of the pipeline applied in the present study is
illustrated in Figure 1.
Chemical Materials. Description of the solvents, chemicals,
and authentic standards used can be found in Supporting
Information.
Samples. Research ethics committee approval (RREC 2989
and RREC 3199) and patient informed consent was obtained
for the collection of tissue specimens from abdominal aortic
aneurysm repair surgery and carotid and femoral endarter-
ectomy. Analyzed tissue samples consisted of four groups of
patients: 26 abdominal aortic aneurysm (AAA), 52 carotid
stenosing plaques (CAR), 26 femoral stenosing plaques (FEM)
and 16 intimal thickening (INT). Samples obtained from
endarterectomies have been previously described.19 A table
Figure 1. Schematic of the analytical pipeline applied in the present
study. Following two consecutive tissue extraction procedures
(aqueous followed by organic) each extract was handled separately
up to the point of data integration, where a pathway mapping step was
further applied to the combined data set. MeOH: Methanol. DCM:
Dichloromethane. QC: Quality control. DDA: Data dependent
acquisition (unbiased precursor ion selection for MS/MS), MSE:
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with patient demographics can be found in Supporting
Information Table S-1.
Metabolite Extraction. Aqueous Extraction. Tissue
samples (153−416 mg) were loaded into bead beating tubes
(Percellys Steel-Kit) preloaded with three steel beads. A
prechilled methanol(MeOH)/water solution (1:1), was added
to the tissue samples. The volume of the solution was adjusted
according to weight of the sample starting at a maximum weight
with 1.5 mL, and reduced proportionally to sample weight (100
μL of solvent/28 mg of tissue). Tissue lysis and metabolite
extraction was performed using a bead beater (Bertin
Technologies) after freezing on dry ice. The bead beater was
vibrating at 6500 Hz for 40 s and 2 plus 2 cycles were
performed separated by freezing of the samples on dry ice. Bead
beating was followed by centrifugation (Eppendorf, Centrifuge
5417R, Germany) at 13000g for 20 min, at 4 °C. Aliquots of
100 μL (∼25 mg of tissue/100 μL of aliquot) of the
supernatant were obtained into Eppendorf tubes. Samples
were spun in a vacuum concentrator for 3 h at 45 °C
(Eppendorf Concentrator Plus, V-AQ mode) until dry and
stored at −40 °C until analysis.
Organic Extraction. Following aqueous extraction a solution
of prechilled dichloromethane(DCM)/MeOH (3:1) was added
to the residual pellet. The volume of the solution was
proportional to the sample weight (as described in previous
paragraph; aqueous extraction). Samples were frozen on dry ice
and reloaded into the bead beater (2 cycles, 6500 Hz, 40 s).
Samples were then centrifuged at 13000g for 20 min, and 100
μL (∼25 mg of tissue/100 μL of aliquot) of organic phase
supernatant was subsequently aliquoted into glass vials.
Samples were allowed to evaporate at room temperature in
an extractor hood overnight and stored at −40 °C until
analysis.
HILIC-UPLC-MS Analysis of Aqueous Extracts. UPLC-
MS Analysis. The aqueous extracts of the tissue samples were
reconstituted in 200 μL of solvent mixture of H2O/ACN
(5:95) and transferred into Total Recovery vials (Waters Corp,
USA), after centrifugation for 20 min at 13000g, 4 °C.
UPLC separation was conducted using an Acquity UPLC
System (Waters Corp, USA). An Acquity UPLC BEH HILIC
2.1 × 100 mm, 1.8 μm, column (Waters Corp, USA) was used.
Column temperature was set at 35 °C. Mobile phase A
consisted of acetonitrile (ACN)/water (95:5) and mobile phase
B ACN/water (50:50). In both solutions ammonium acetate
was diluted to 10 mM and formic acid to 0.1%. The elution
gradient was set as follows: 99% A (0.0−2.0 min; 0.4 mL/min),
99−45% A (2.0−8.0 min; 0.4 mL/min), 45−1% A (8.0−9.0
min; 0.4 mL/min), 1% A (9.0−9.1 min; 0.4−0.8 mL/min), 1%
A (9.1−11.0 min; 0.8 mL/min), 1−99% A (11.0−11.1 min; 0.8
mL/min), 99% A (11.1−19.0 min; 0.8 mL/min), 99% A
(19.0−19.1 min; 0.8−0.4 mL/min), 99% A (19.1−23.0 min;
0.4 mL/min). An injection volume of 10 μL was used for both
positive and negative ionization polarity modes. The
autosampler was set at 4 °C. Mass spectrometry was performed
using a Premier Q-TOF (Waters MS Technologies Ltd., UK)
with an electrospray ionization (ESI) source. MS conditions
can be found in Supporting Information.
A standard QC strategy20 was used for the UPLC-MS
analysis. Brieﬂy, a pooled sample (Quality Control Sample,
QC) of the reconstituted extracts was prepared. This sample
was injected at least 10 times before initiating the run, in order
to condition the column. Then the sample was reinjected once
at the beginning, every 10 sample injections, and at the end of
the run (total of 13 injections) to assess instrument stability
and analyte reproducibility. Following sample analysis a QC
sample dilution series (1:2, 1:4, 1:8) in the reconstitution
solvent mixture was performed and followed by extraction
blank sample. This strategy is also illustrated in Figure 1.
Data Extraction. Collected data were subjected to peak-
picking and grouping using MarkerLynx XS (Waters Inc., v4.1)
software. Parameters used are presented in Supporting
Information Table S-2. Values were reported as height of
intensity peaks. Samples were normalized to total intensity.
Values were multiplied by 10 000 prior to statistical analyses.
The dilution series was used here to remove peaks that did not
respond to dilution. This was achieved by applying multivariate
statistics to the QC samples and dilutions and removing
features (variables) that did not vary in intensity according to
the dilutions applied. Additionally, as the local anesthetic
lidocaine is typically locally administered to patients prior to
performing carotid endarterectomy, features attributed to
lidocaine and its metabolite hydroxylidocaine were removed
from further statistical analyses.
RP-UPLC-MS Analysis (Lipid Proﬁling) of Organic
Extracts. UPLC-MS Analysis. The organic extracts of the
tissue samples were reconstituted in 500 μL of the solvent
mixture of water/ACN/isopropanol (ISP) (1:1:2) and trans-
ferred into Total Recovery vials (Waters Corp, USA), after
centrifugation for 10 min at 5000g and 4 °C.
UPLC separation was conducted using an Acquity UPLC
System (Waters Corp, USA). An Acquity UPLC CSH C18 2.1
× 100 mm, 1.7 μm, column (Waters Corp, USA) was used.
Column temperature was set at 55 °C and ﬂow rate at 0.4 mL/
min. Mobile phase A consisted of ACN/water (60:40) and
mobile phase B ISP/ACN (90:10). In both solutions
ammonium formate was diluted to 10 mM and formic acid
to 0.1%. The elution gradient was set as follows: 60−57% A
(0.0−2.0 min), 57−50% A (2.0−2.1 min; curve 1), 50−46% A
(2.1−12.0 min), 46−30% A (12.0−12.1 min; curve 1), 30−1%
A (12.1−18 min), 1−60% A (18.0−18.1 min), 60% A (18.1−
20.0 min). Injection volumes of 3 and 7 μL were used for
positive and negative ionization modes, respectively. The
autosampler was set at 4 °C. Mass spectrometry was performed
using a Xevo G2 QTof (Waters MS Technologies, U.K.) with
an electrospray ionization (ESI) source. Both MS and MSE data
scans were acquired. MS conditions can be found in Supporting
Information. The same QC strategy was followed as for the
HILIC-UPLC-MS analysis.
Data Extraction. After acquisition, data were centroided
(m/z spectra peaks are automatically detected and their
centroid is calculated based on the average m/z value and
weighted by the intensity). This was followed by peak-picking
and grouping using MarkerLynx XS (Waters Inc., v4.1)
software. Parameters used are presented in Supporting
Information Table S-2. Values were reported as peak intensity
(area). Saturated peaks (as identiﬁed by the MassLynx
software) were removed prior to total area normalization.
Values were multiplied by 10 000 prior to statistical analyses.
Safety Considerations. MeOH and ACN are known to be
harmful while DCM is harmful, considered toxic and may be
carcinogenic. These solvents should be handled in a fume hood
and avoid skin contact and inhalation. Safety considerations
include obtaining appropriate training prior to using these
solvents and using appropriate waste disposal since they can
impose an environmental hazard.
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Statistical Analysis. Multivariate data analysis (MVDA)
was conducted using the SIMCA package (version 13.0.2.;
Umetrics, Sweden). Principal components analysis (PCA) and
orthogonal projection to latent structures discriminant analysis
(OPLS-DA) were employed to examine UPLC-MS data in a
multivariate setting. Prior to model ﬁtting, features were
subjected to Pareto scaling. Two-tailed t tests (assuming
unequal variance), and coeﬃcients of variation % (CV%) were
calculated in Microsoft Oﬃce Excel 2007.
Metabolite Structural Assignment. For metabolite
structure assignment, accurate m/z measurements of detected
chromatographic peaks were ﬁrst matched to metabolites from
online MS databases (Metlin,21 HMDB,22 and Lipidmaps23).
After an assessment of retention time and isotopic pattern,
tandem MS (UPLC-MSE and UPLC-MS/MS) fragmentation
pattern was employed for further structural elucidation.
Assignment according to fragmentation pattern was dependent
on the ability to obtain spectra with adequate signal. Further, an
authentic standard of the metabolite was run using identical
UPLC-MS/MS conditions and the detected m/z was matched
to (1) the retention time and, where possible, (2) the MS/MS
spectrum obtained from the sample under identical exper-
imental conditions. Matching to an authentic standard was
dependent on commercial availability and was pursued for small
molecules. In Supporting Information Table S-3, the level of
assignment is provided for every annotation according to the
following criteria: (1) Accurate mass matched to database
indicating tentative assignment, (2) accurate mass matched to
database and tandem MS spectrum matched to in silico
fragmentation pattern, (3) tandem MS spectrum matched to
database or literature, (4) retention time (RT) matched to
standard compound, and (5) MS/MS spectrum matched to
standard compound.
Pathway Mapping. For pathway mapping the KEGG
database24 (July 10, 2014 Update) and Ingenuity Pathway
Analysis software (IPA) (Build, 313398M; Version, 18841524)
were used.
Venn Diagrams. Venn diagrams were constructed using
online available software (http://bioinfogp.cnb.csic.es/tools/
venny/index.html).
■ RESULTS AND DISCUSSION
In the present study a simple pipeline (Figure 1) was designed
in order to expand metabolome coverage and analyte
reproducibility in tissue samples. The well recognized
limitations of a single chromatographic mode to deliver broad
metabolite coverage motivated the utilization of both RP- and
HILIC-UPLC-MS columns. Chromatographic conditions were
optimized to enhance separation of the detected compounds.
Further, we provide an experimental setup for untargeted
metabonomic settings, in order to support eﬃcient metabolite
assignment and increase conﬁdence of potential biomarkers. In
addition, analytical and RT reproducibility were also assessed
using the 13 QC samples, followed by an evaluation of
metabolome coverage. Pathway mapping methodologies were
used to assess the extent of coverage of biological pathways and
functions. Lastly, an application to cardiovascular disease
related samples (n = 120) illustrated the ability of the pipeline
to deliver disease related metabolic proﬁles. The successful
analysis of a biologically active tissue with high lipid content as
a matrix ensures the robustness and wide applicability of the
developed methodologies.
Tissue Lysis and Extraction. Previous work from our
laboratory18 has demonstrated that consecutive extractions, that
is, polar extraction followed by organic (rather than a bilayer
format) delivers higher reproducibility in tissue extraction.
Thus, consecutive extraction was applied here (Figure 1).
Moreover, the use of bead-beating for tissue lysis has also been
demonstrated to be superior to other lysis methodologies, such
as manual grinding and electric homogenizer.6 For tissue lysis,
bead-beating was used with preference for steel beads, as from
preliminary studies, it was observed that steel beads were
superior in homogenizing the calciﬁed parts of the plaque
tissues, as compared to zirconium beads.
Optimization of HILIC-UPLC-MS Analysis of Aqueous
Extracts. For HILIC chromatographic conditions, no pH
mobile phase adjustment was chosen, opting to keep the
method unbiased in terms of basic or acidic compounds. By
using arterial tissue extracts, tests with longer isocratic initial
conditions did not result in improved chromatographic
separation.
The ability of the gradient program to adequately re-
equilibrate the system was also assessed. The re-equilibration
part of the gradient program was extended to accommodate
adequate stability prior to each injection, while ensuring
analysis did not exceed 23 min per sample making it attractive
for application in large-scale studies.
The eﬀect of the reconstitution solvent on chromatographic
performance was also assessed using diﬀerent percentages of
ACN. Speciﬁcally, three diﬀerent proportions of ACN were
used (50%, 75% and 95% ACN) to reconstitute pooled tissue
extracts. This test aimed to explore the hypothesis that low
percentages of ACN in the reconstitution solvent may disturb
the major partitioning mechanism between the aqueous coating
formed in the HILIC column on the surface of the stationary
phase of the HILIC column and the analytes.25 It was found
that when ACN was present at <95%, a number of
chromatographic peaks were split, resulting in two peaks -one
eluting at the beginning of the gradient program, and another at
a higher retention time (Supporting Information Figure S-1). It
was further observed that low percentages of ACN could also
distort the peak shape (Supporting Information Figure S-1).
These observations were further veriﬁed using standard
compounds dissolved in diﬀerent proportions of ACN
(Supporting Information Figure S-2). Another advantage of
using 95% ACN was that it made the column less exposed to
precipitating proteins, as proteins would have been precipitated
prior to injection. Preventing proteins from precipitating and
eventually blocking the column can be a challenge in HILIC
analysis, due to the highly organic initial solvent proportions of
the mobile phase system, causing the proteins dissolved in the
sample to precipitate as they enter the column. With the
described methodology it was observed that no increase in
system pressure was detected after 300 injections of tissue
extracts (Supporting Information Figure S-3), indicating that
there was likely no buildup of proteins in the column. However,
using a highly organic solution for reconstitution could
inﬂuence the desolvation of polar compounds. It was observed
that the sensitivity for some of the polar compounds (detected
toward the end of the chromatogram) was aﬀected, although
these compounds were still detectable (Supporting Information
Figure S-4).
Using the HILIC method it was noted that low levels of lipid
classes, such as triacylglycerol (TG), diacylglycerol (DG), and
cholesteryl ester (CE) eluted with the solvent front
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(Supporting Information Figure S-5), while several phospho-
lipids eluted in a narrow range in the middle part of the
chromatogram (Figure 2C and D). This characteristic
demonstrates an advantage of HILIC over RP chromatography
since lipid build-up in the column is a known weakness of RP.
Additionally, in RP methods, lipid elution requires longer
gradients and can span a wide range of the chromatographic
run, which could aﬀect the detection of smaller molecules.
Lipids are highly abundant in biological matrices and are
expected in higher concentrations in tissue relevant to
cardiovascular disease, such as atherosclerotic plaques. Most
importantly, it became clear from early optimization experi-
ments that the RP column could adequately retain polar
compounds (Supporting Information Figure S-6). The
capabilities of the HILIC method were also assessed using
adipose tissue aqueous extracts (Supporting Information Figure
S-7).
Optimization of Lipid Proﬁling via RP-UPLC-MS.
Optimization of the chromatographic separation stage of the
lipid proﬁling methodology was initially conducted using lipid
standard mixtures. A charged surface hybrid (CSH) column
was used as it improved the separation of lipid moieties
between classes as well as within each class, spanning a wide
range of lipophilicity. Interclass separation is important as it can
assist in structural assignment of the lipids. Moreover, intraclass
separation can reduce ion suppression induced by coeluting
lipids of the same class. In fact, the use of HILIC
chromatography for lipid proﬁling was abandoned due to the
insuﬃcient intraclass lipid separation (Figure 2) and inadequate
partitioning of neutral lipids (Supporting Information Figure S-
5).
The CSH column also demonstrated short re-equilibration
times between injections, reducing analytical run length and
increasing throughput. Lastly, the use of ISP in the mobile
phase and high column temperature provided the ability to
elute highly lipophilic compounds such as TGs and CEs that
would otherwise be strongly partitioned into the stationary
phase, thus reducing chromatographic performance and causing
carry over phenomena. We did not observe signiﬁcant carry
over eﬀects of any molecular class (Supporting Information
Figure S-8).
The separation ability of the CSH column was further
assessed by using isomers and cis- and trans- stereoisomers of
the phosphatidylglycerol (PG) lipid species. Firstly, separation
the cis- compounds of the PG(18:1(9Z)/18:1(9Z)) against
PG(18:0(9Z)/18:2(9Z)) was demonstrated. Additionally,
separation of cis-PG(18:1(9Z)/18:1(9Z)) and trans-PG(18:1-
(9E)/18:1(9E)) was achieved (Supporting Information Figure
S-9). Lastly, the applicability of this column for analysis of real
biological samples was assessed by testing chromatographic
performance using rat, murine and human plasma organic
extracts and bovine liver, human arterial and adipose tissue
organic extracts (Figure 2 and Supporting Information Figure
S-7).
UPLC-MS Experimental Setup. The use of QC samples to
assess reproducibility and instrument performance and stability
is preferred in metabolic proﬁling studies.10,18,20 We herein
employed the QC format and demonstrated the usefulness of
this approach to assess reproducibility using both MVDA
(Figure 3) and univariate statistics (Table 1 and Figure 4). We
also included in the analysis several extraction blank samples
(Figure 1). The sample preparation procedure and solvent
Figure 2. Base peak intensity chromatograms demonstrating the elution times of some of the major metabolite classes detected in (A) positive
electrospray ionization mode (ESI+), (B) negative electrospray ionization mode (ESI−) from the HILIC-UPLC-MS analysis of the aqueous extracts;
(C) ESI+ and (D) ESI− from the lipid proﬁling analysis of the organic extracts.
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impurities can introduce ions unrelated to the analyzed matrix.
By including extraction blank samples we were able to easily
identify and remove features present in the blank samples but
not the matrix of interest, using multivariate statistics
(Supporting Information Figure S-10). Verifying that the origin
of the ion of interest is matrix-related can minimize the
possibility of artifacts.
We also included dilutions of the pooled (QC) samples to
assess the ability of each ion to respond to ﬂuctuations in
concentration (Figure 1). An initial assessment of the response
to dilutions was also performed−using only the 2-fold dilution -
prior to initiating analysis. The injection volume was adjusted
to optimize intensity response to dilution. The dilution series
injected at the end of the runassisted in identifying features
that were not responding to the subsequent dilutions
(Supporting Information Figure S-11). Features demonstrating
an erratic behavior were observed in the HILIC analysis. This
was predominantly the case with lipid moieties of the same
class. We hypothesized that this may be due to the coelution of
lipids and a resulting suppression of their signals as a result of
simultaneous ionization in the ESI source. These features were
removed from further analysis (Supporting Information Figure
S-11). In literature, there are suggestions on how the dilution
series can assist in increasing biomarker conﬁdence.26
Collision-induced dissociation (CID) experiments were
applied to the QC sample in order to obtain structural
information for hundreds of detected ions. This was conducted
during the conditioning step (Figure 1). Obtaining fragmenta-
tion patterns of molecules of interest during the original
proﬁling run can save the analyst time and frustration, since
variations in retention time and instrument performance can
occur when returning to the instrument for tandem-MS
experiments after long periods. Both unbiased UPLC-MS/MS
acquisition (DDA, data dependent acquisition), as well as
acquisition with no precursor ion selection (UPLC-MSE) were
employed. The DDA MS/MS experiments can provide
fragments speciﬁcally attributed to the precursor ion. On the
other hand, the MSE approach,27 in combination with
chromatographic separation, proved very useful for structural
assignment of metabolite classes, as it can provide the analyst
with retention times of characteristic secondary ions upon
fragmentation, known to be speciﬁc for metabolite classes.
Figure 5 demonstrates how a characteristic fragment of
carnitines (Figure 5B) assisted in identifying several molecules
from this group of compounds. Lastly, we use the same
gradient program for analyzing in positive and negative
ionization mode as it can provide valuable complementary
information aiding toward an easier metabolite structural
assignment.
Reproducibility. Chromatographic Reproducibility. It has
been reported that chromatographic reproducibility can be a
limiting factor especially with HILIC columns,4,15 ultimately
aﬀecting data quality. Peak retention time (RT) reproducibility
was evaluated using the 13 QC samples interspersed
throughout the run to calculate the CV%. The most abundant
ions per RT window in the QC samples were used for the
evaluation (Supporting Information Figure S-12). The peaks of
these ions demonstrated an RT CV % values of <0.5%.
Analytical Reproducibility. Using the 13 injections of the
QC samples, two statistical approaches were applied to evaluate
the analytical reproducibility of the two methodologies in terms
of detected intensities: (1) using PCA as a MVDA method to
test reproducibility and (2) by calculating the CV% of detected
peaks as a univariate way. The PCA demonstrated a tight
grouping of the QC samples (Figure 3), indicative of their high
reproducibility across the run and conﬁrming that the variation
observed between the samples (n = 120) was nonsystematic,
but biologically related. Additionally, >80% of the abundant
features demonstrated CV values of <30% (Table 1). Abundant
features were considered to be the features for which
chromatographic peaks could be detected in all of the 13 QC
Figure 3. Scores plots of principal components analysis (PCA) models
generated from the UPLC-MS analyses of tissue extracts, demonstrat-
ing the biological samples and the quality control samples (QC). The
tight grouping of QCs as compared to the distribution of the biological
samples highlights the reproducibility and instrument stability through
the run. (A) Positive electrospray ionization mode (ESI+) and (B)
negative electrospray ionization mode (ESI−) from the HILIC-UPLC-
MS analysis of the aqueous extracts. (C) ESI+ and (D) ESI− from the
lipid proﬁling analysis of the organic extracts.











CV %a < 10
abundant features
with CV %a 10−20
abundant features




CV %a > 30
lipid proﬁling −positive mode 9884 2582 2095 (81) 1080 702 313 487
lipid proﬁling −negative mode 4804 1410 1164 (83) 619 338 207 246
HILIC−positive mode 5479 1378 1123 (81) 403 464 256 255
HILIC−negative mode 3483 1240 1096 (88) 344 525 227 144
aCV % = Coeﬃcient of variation %
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samples. It is important to exclude features for which the peak
intensity did not pass the peak-picking intensity S/N threshold
(or otherwise not detected) as they could skew the value of the
CV % calculation. Table 1 summarizes the CV% reproducibility
analysis of all employed methodologies.
The high retention time and analytical reproducibility of the
detected ions demonstrate that the presented methodologies
can deliver the robustness required by a metabolic proﬁling
study.
Improvement in Metabolome Coverage by Combin-
ing HILIC and RP Methodologies. The scientiﬁc community
is constantly striving to expand metabolome coverage. This
forces analysts to combine diﬀerent analytical platforms and
methods in order to increase the number of robustly detected
Figure 4. Structurally assigned metabolites with coeﬃcient of variation (CV%) values for each analysis where they were detected. HL: HILIC-UPLC-
MS. LP: Lipid proﬁling. Pos: Positive electrospray ionization mode. Neg: Negative electrospray ionization mode.
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metabolites. Multiplatform analyses are particularly relevant
when both polar and nonpolar metabolites require analysis.
Here, two UPLC-MS chromatographic methods were
combined to expand metabolome coverage resulting in a total
of 226 unique metabolite structural assignments (Figure 4 and
Supporting Information Table S-3), ranging from polar (e.g.,
amino acids, creatine, carnitines, purines, and pyrimidines) to
highly lipophilic metabolites (e.g., TGs and CEs). The two
methods demonstrated high complementarity, with only 20
intermethod metabolites detected (Figure 6). These metabo-
lites corresponded to highly abundant lipid compounds with
amphiphilic properties. With the lipid proﬁling method, 97
metabolites were uniquely assigned, with 29 commonly
detected in both polarities (Figure 6). The HILIC method
provided 109 unique metabolites with 18 detected by both of
the HILIC polarity modes (Figure 6).
Several molecules were preferentially ionized in only one of
the MS polarities. This was particularly obvious with compound
classes such as TGs, CEs and acyl-carnitines preferentially
ionizing in positive mode, while classes such as free fatty acids,
phosphatidylinositols, phosphatidylserines and sulfated com-
pounds preferentially ionized in negative mode. Additionally,
metabolites detected by both polarities can frequently provide
essential information to guide structural assignment. In fact, for
several species tandem MS spectra from both polarities were
required for achieving structural assignment, thus demonstrat-
ing the necessity of analyzing both intramethod polarities with
the same chromatographic gradient. Overall, a substantial
amount of extra information was obtained by using both
polarity modes, resulting in expansion of metabolome coverage
and assisting metabolite structure assignment.
It should be noted that the detected metabolite list (Figure 6
and Supporting Information Table S-3) does not represent all
the metabolites that can be detected by the described
experiments, nor exhausts the ability of these methods for
detection of additional metabolites. Factors such as tissue
speciﬁcity can aﬀect the concentrations or presence of speciﬁc
molecules. Moreover, several ions could not be structurally
assigned due to ambiguity of their m/z, inadequate tandem MS
information, or absence from online databases and are not
further described here. At the same time, several administered
drugs were also detected, such as the local anesthetics
bupivacaine, lidocaine and their metabolites such as hydrox-
ylidocaine. However, they are not further discussed as the study
focuses predominantly on endogenous compounds.
Using the HILIC method, carnitine, carnitine derivatives,
such as acylcarnitines incorporating fatty acyl chains (FAC) in
the range of 22C to acetylcarnitine, were detected. The
chromatographic proﬁle of the structurally assigned carnitine
derivatives and carnitine is presented in Figure 5. Additionally,
nine α-amino acids (α-AA), and α-AA derivatives, such as N-
acetylmethionine, purines and pyrimidines (Figure 2), as well as
sphinganine and the 16C and 18C sphingosines, organic acids
(benzoic and salicylic), nicotinamide and 1-methylnicotina-
mide, creatine and creatinine, betaine, glycerophosphate
derivatives, sugars, acylcholines, could be indentiﬁed in the
aqueous tissue extracts.
Using the lipid proﬁling method we detected phospholipids
from the classes of: phosphatidylcholines, phosphatidylethanol-
amines, phosphatidylinositols, phosphatidylserines, phosphati-
dylglycerols, lysophosphatidylcholines, and lysophosphatidyle-
thanolamines (Figure 2). Additionally, sphingolipids with
diﬀerent backbone lengths and degree of unsaturation were
identiﬁed (d18:0, d18:1, d18:2, d16:1 and d17:1). Sphingoli-
pids detected included ceramides, sphingomyelins, phosphati-
dylethanolamine-ceramides (PE-Cer), mono-, di-, tri-, and
tetra-hexosylceramides. Free fatty acids were another lipid class
detected using the negative mode of the lipid proﬁling method
(Figure 2B). FFA in the range of 16−22C were detected, while
cis- and trans- stereoisomers (elaidic and oleic acid; linoelaidic
and linoleic acid) could be chromatographically resolved
(Supporting Information Figure S-13). Glycerolipids were
detected in the form of DGs and TGs and in a wide range of
Figure 5. (A) Proﬁle of extracted ion chromatograms (XIC) of
carnitine, acylcarnitines, and other carnitine derivatives (inset shows
expansion of the retention time window of 4.80−5.15 min) using the
HILIC-UPLC-MS method on aqueous extracts in positive mode.
Unlabeled peaks represent unrelated isobaric ions. (B) XIC of a
characteristic acyl carnitine fragment obtained from MSE analysis.
Figure 6. A Venn diagram demonstrating commonly and exclusively
detected metabolites for the employed analyses and electrospray
ionization modes. The vast number of metabolites robustly detected
by only one of the methods demonstrates the complementarity of the
HILIC-UPLC-MS and the lipid proﬁling methods when applied on
the aqueous and organic extracts, respectively. The diagram is based
only on structurally assigned metabolites. ESI+: positive electrospray
ionization mode, ESI-: negative electrospray ionization mode.
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incorporated FAC. Finally, sterol lipids such as cholesterol,
cholesteryl esters, oxidized cholesteryl esters (Figure 2A) and
cholesterol sulfate were identiﬁed. Lipid structural assignments
would typically include elucidation of FAC length and degree of
unsaturation. However, the double bond and sn- positions
could not be elucidated using the MS approach employed here.
Finally, it should be highlighted that the untargeted format of
the two methodologies is capable of identifying previously
uncharacterized compounds, a critical advantage compared to
targeted approaches. An example is the previously unreported
forms of PE-Cers (PE-Cer(d18:1/16:0) and PE-Cer(d18:1/
24:1)) (Figure 4 and Supporting Information Table S-3).
Additionally, acylcholines, such as arachidonoylcholine and
palmitoylcholine (Figure 4 and Table S-3), were not listed in
the MS databases used.
Pathway Mapping. Out of the 229 assigned metabolites,
187 could be mapped using the KEGG24 database and a KEGG
ID could be assigned (Supporting Information Table S-3). A
total of 100 KEGG IDs were considered unique. Using the
KEGG mapper (http://www.genome.jp/kegg/mapper.html), a
mapped overview of the primary human metabolic pathways
demonstrated 49 mapped metabolites (Supporting Information
Figure S-14). However, it was observed that some primary
metabolic pathways were lacking representation. This was
evident with the central carbohydrate metabolism, fatty acid
metabolism (fatty acids <16C) and glycan metabolism.
Coverage of these pathways will be subsequently pursued
with appropriate platforms and methods, along with eﬀorts for
further unbiased expansion of the range of the detected and
structurally assigned metabolites. Nonetheless, using the IPA
software a wide range of canonical pathways, biological
functions and disease pathways could be covered by the
assigned metabolites. Up to 89 out of the 100 KEGG IDs
imported in the IPA software were recognized. These
metabolites could be mapped by IPA to 182 canonical
pathways (Supporting Information Figure S-15 and Spread-
sheet S-1). Most importantly, 60 unique metabolites could be
associated and mapped to vast number of diseases and
biological functions (Supporting Information Figure S-16 and
Spreadsheet S-2). These included lipid accumulation and
concentration, cancer, inﬂammation, cell death and survival,
proliferation, apoptosis, necrosis, peroxisomal disorder and cell
diﬀerentiation. Additionally, 36 assigned metabolites could be
mapped being involved in 99 toxicity functions (Supporting
Information Figure S-17 and Spreadsheet S-3), such as liver
damage, cardiac damage, and renal failure.
Application to Cardiovascular Disease. According to the
World Health Organization (WHO), CVD is the leading cause
of mortality in the western world. Deaths associated with CVD
are mainly related to atherosclerosis and hypertension. Here,
we used diseased human tissue from the arterial tree to assess
the ability of the RP lipid proﬁling and the HILIC polar
phenotyping methods to deliver metabolic proﬁles relevant to
tissue phenotype. Human tissues samples (n = 120) were used,
obtained from 26 abdominal aortic aneurysm (AAA) tissue, 52
carotid stenosing plaque (CAR), 26 femoral stenosing plaques
(FEM), and 16 from intimal thickening plaque-free tissue
(INT). The tissue used is known to be biologically active with
presence of several inﬂammatory factors contributing to the
disease process. Additionally, plaque tissue incorporates high
lipid content with macroscopically discrete substructure. These
features (high lipid and protein content) of the chosen analyzed
tissue demand robust pipeline and tools to avoid compromising
optimal performance. The successful metabolic proﬁling of
such tissue, as evidenced by the high reproducibility and
number of metabolites detected, further demonstrates the
robustness of our pipeline and developed methodologies.
Using OPLS-DA ﬁtted models to explore diﬀerences in tissue
metabolic phenotypes, separation of the four tissue groups was
apparent as demonstrated by the cross-validated scores plots in
Figure 7, along with models characteristics. The model
characteristics presented well-ﬁtted models with high predictive
values (Q2Y:0.44−0.52; Figure 7). Intriguing ﬁndings from this
Figure 7. Cross-validated scores plots of orthogonal projection to
latent structures−discriminant analysis (OPLS-DA), demonstrating
separation between the UPLC-MS analyses of the tissue extracts from
the four diseased groups. (A, B) Positive electrospray ionization mode
(ESI+) and (C, D) negative electrospray ionization mode (ESI−)
from the HILIC-UPLC-MS analysis of the aqueous extracts. (E, F) ESI




Anal. Chem. 2015, 87, 4184−4193
4192
data set were (1) manifested diﬀerences between the two
plaque groups CAR and FEM, since it demonstrates that
plaques from diﬀerent locations express distinct metabolic
activity, and (2) the similarities observed by the FEM and AAA
groups. Loadings plots showing the metabolites driving the
separations between the sample groups can be found in
Supporting Information Figure S-18. However, biological
interpretation of these ﬁndings exceeds the scope of this
paper and is not further discussed. Biological interpretation for
the comparison between INT tissue and CAR and FEM
plaques has been previously described.19
■ CONCLUSIONS
We demonstrate that a combination of RP- and HILIC-UPLC-
MS methodologies delivers improved ability to achieve broad
metabolome coverage of compounds with diverse physico-
chemical properties. Additionally, these chromatographic
methods are highly complementary, further illustrating the
necessity for rationally combining RP and HILIC methods for
analyzing organic and aqueous tissue extracts, respectively.
Importantly, this pipeline can cover a wide range of metabolic
pathways and biological functions, while their untargeted
format allows for the detection of previously unknown
metabolites. The implementation of DDA and MSE acquisitions
on pooled QC samples within the analytical run, permits
simultaneous collection of metabolite structural information
and reduces the time of the analytical pipeline. The described
pipeline is generic and applicable to other tissue types. In
future, the described methodologies will be complemented with
additional methods and platforms to address gaps in




Further information on chemical materials, MS and data
processing parameters, tables of patient demographics and
assigned metabolites, and ﬁgures of: HILIC and RP
optimization and performance; HILIC and RP comparison;
additional applications on adipose tissue, liver tissue and plasma
samples; further data processing; and pathways analysis. This
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